Biotech IV Monitor

ELVN — Enliven Therapeutics Inc.

$3.2B market cap · 1 upcoming readout tracked

Clinical trial readout dates for Enliven Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2028.

Next readoutDecember 2028in ~25 months
Upcoming readouts11 Phase 3
Market cap$3.2B
Cash & investments$884M~32 quarters at last loss rate
Recent 8-K filings1latest 2026-11-05

Upcoming readouts

Phase 3 ELVN-001
Chronic Myeloid Leukemia (CML); Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Pos · NCT07905183
December 2028
Not Yet Recruiting

Cash position

Enliven Therapeutics Inc. reported $884M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $28M; at that rate the cash would last about 32 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05

Companies working on similar indications

Discussion

No messages yet. If you follow ELVN, you can start the conversation.
Track ELVN in real time
See live implied volatility for ELVN and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on ELVN
Contact — questions or corrections about ELVN: dukeupt@gmail.com